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High citrate diet delays progression of renal insufficiency in the
ClC-5 knockout mouse model of Dent’s disease.
Background. Dent’s disease, an X-linked renal tubular dis-
order, is characterized by low-molecular-weight proteinuria,
hypercalciuria, nephrocalcinosis, nephrolithiasis, and progres-
sive renal failure. Dent’s disease results from mutations of the
voltage-gated chloride channel CLC-5.
Methods. We studied the effect of zero and high citrate diet
on renal function of ClC-5 knockout mice and wild-type mice.
The mice were placed in metabolic cages from which the urine
was collected. Mice were sacrificed to obtain serum and tissues
for analysis.
Results. ClC-5 knockout mice fed zero or high citrate diet
had significantly increased urinary calcium excretion compared
with wild-type mice fed the same diets. Nine-month-old ClC-5
knockout mice on a zero citrate diet had significantly decreased
glomerular filtration rate (GFR), whereas 9-month-old ClC-5
knockout mice on a high citrate diet had normal renal function.
ClC-5 knockout mice fed a zero citrate diet had significantly
increased tubular atrophy, interstitial fibrosis, cystic changes,
and nephrocalcinosis compared to ClC-5 knockout mice fed a
high citrate diet. Transforming growth factor-b1 (TGF-b1) was
significantly increased in 9-month-old ClC-5 knockout mice on
zero citrate diet compared to 9-month-old wild-type mice on
the same diet.
Conclusion. High citrate diet preserved renal function and
delayed progression of renal disease in ClC-5 knockout mice
even in the apparent absence of stone formation. We conclude
from this that long-term control of hypercalciuria is an impor-
tant factor in preventing renal failure in these mice.
Dent’s disease is an X-linked renal tubular dis-
order with features of Fanconi syndrome, includ-
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ing low-molecular-weight proteinuria, phosphaturia,
aminoaciduria, glycosuria, renal potassium-wasting, uri-
cosuria, and impaired urinary acidification [1]. The
disease is also characterized by hypercalciuria, nephro-
calcinosis, and kidney stones. In addition one third of
the patients present with rickets [2]. Dent’s disease is
caused by mutations of the CLCN5 gene [3]. CLCN5
encodes CLC-5, a member of the CLC family of voltage-
gated chloride channels [4] which conducts outwardly
rectifying chloride currents that are activated by strong
depolarizing voltages [5]. Mutations of CLC-5 that are
found in Dent’s disease patients abolish or markedly re-
duce these chloride currents [6, 7]. The highest expres-
sion of CLC-5 is in the nephron, where it is localized to
the proximal tubule, the thick ascending limb, and the a-
intercalated cells of the collecting duct [8–10]. In the prox-
imal tubule, CLC-5 is located in the early endosomes that
form part of the receptor-mediated endocytic pathway
[8–10]. The megalin receptor-mediated endocytic path-
way, reabsorbs low-molecular-weight proteins less than
70 kD such as b 2-microglobulin and the vitamin D bind-
ing protein that are freely filtered through the glomerulus
of the kidney [11, 12]. This pathway is defective in Dent’s
disease.
Of all patients with various types of nephrolithiasis in-
cluding Dent’s disease, hypercalciuria is present in more
than half [13, 14]. With increased urinary calcium excre-
tion, the ionic activity of calcium increases and urine be-
comes saturated with stone-forming calcium salts which
tend to crystallize [15, 16]. Besides hypercalciuria, hypoc-
itraturia is another very common metabolic risk factor for
stone formation in adult and pediatric populations [17].
Citrate decreases ionized calcium in the urine by com-
plexing calcium [18, 19], and citrate also has a direct in-
hibitory effect against crystallization of calcium oxalate
and calcium phosphate [18, 19]. Potassium citrate is one
of the drugs used for prevention of recurrent calcium ox-
alate nephrolithiasis [20, 21].
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Previous studies [22, 23] and preliminary data have
established that the ClC-5 knockout mouse model we
have developed has most of the aspects of human
Dent’s disease. These mice, lacking the ClC-5 chan-
nel, develop polyuria, low-molecular-weight proteinuria,
aminoaciduria, glycosuria, and hypercalciuria. The daily
urinary excretion of calcium is on average about twofold
higher in ClC-5 knockout mice, an increase that is similar
to that observed in patients with Dent’s disease [2, 24, 25].
Experiments in ClC-5 knockout proximal tubules evalu-
ating the uptake of various markers of endocytosis such as
b 2-microglobulin [12] have shown that there is decreased
receptor-mediated uptake of low-molecular-weight pro-
teins, causing the low-molecular-weight proteinuria. Dys-
function of ClC-5 channels leads to defective endocytosis
[8] but the actual reason for this is not clear. It has been hy-
pothesized that the loss of ClC-5 leads to defective acidi-
fication of the endocytic compartment [22, 26]. Similarly,
horseradish peroxidase, used as a marker of fluid phase
uptake, showed little uptake in ClC-5 knockout mice [22].
We now show that aging ClC-5 knockout mice have
other attributes of Dent’s disease, including nephrocalci-
nosis, progressive renal disease, progressive fibrosis, and
elevation of transforming growth factor-b1 (TGF-b1), a
renal fibrosis marker. We hypothesized that removal of
citrate from the normal high citrate chow would acceler-
ate the renal disease. Comparing wt and ClC-5 knockout
mice for biochemical markers of renal function such as
blood urea nitrogen (BUN) and creatinine, glomerular fil-
tration rate (GFR), and histologic markers such as inter-
stitial inflammation, tubular atrophy, interstitial fibrosis,
and nephrocalcinosis show that removal of citrate from
the diet accelerates renal insufficiency in ClC-5 knockout
mice. Conversely, high citrate diet preserves renal func-
tion and delays progression of renal disease in this model.
METHODS
Animals, treatments, and diets
All animal use complied with the guiding principles of
the Institutional Animal Care and Use Committee, and
the protocols for this work were approved by this com-
mittee. All mice had unlimited access to water and were
fed a normal laboratory chow from weaning. This chow
contained 0.27% citrate, 0.95% calcium, 0.67% phospho-
rus, 0.27% sodium, 0.66% potassium, with a caloric value
of 4.0 kcal/g, total protein of 23%, and a fiber content of
5.3% (5P07) (LabDiet, Baltimore, MD, USA). This diet
provides a citrate amount that is equivalent to high-dose
human potassium citrate therapy (40 to 100 mEq/day)
[21]. Mice fed this diet are designated high citrate mice.
A second group of mice was given a diet without citrate.
This diet is referred to as zero citrate diet. This diet con-
tained 0.6% calcium, 0.4% phosphorous, 0.1% sodium,
0.64% potassium, a caloric value of 3.9 kcal/g, with a pro-
tein and fiber content of 20% and 4%, respectively (TD
00640) (Harlan Teklad, Madison, WI, USA). Mice fed
this zero citrate diet are designated as zero citrate mice.
Wild-type and ClC-5 knockout zero citrate mice were
sacrificed at the age of 6 months (after being on zero cit-
rate diet for 4 months) or were sacrificed at the age of 9
months (after being on zero citrate diet for 7 months).
Control groups of wild-type and ClC-5 knockout mice
fed a high citrate diet were followed for 6 months,
9 months, 12 months, and 17 months. All mice were placed
in metabolic cages for urine collection, and then sacrificed
to obtain serum and kidneys for histology and protein iso-
lation. At the ages of 2, 4, and 6 months ClC-5 knockout
and wild-type mice were placed in metabolic cages. The
24-hour urine was collected to determine whether the
ClC-5 knockout mice remained hypercalciuric over time
with respect to wild-type mice.
Urine and serum parameters
Urinary creatinine, urea, calcium, sodium, and potas-
sium, as well as BUN, serum creatinine, and calcium were
measured by Animal Diagnostic Laboratory (Baltimore,
MD, USA) or Antech Diagnostics (Lake Success, NY,
USA). Urinary pH was measured with a pH meter 220
(Corning, Corning, NY, USA). Urinary citrate was mea-
sured with a citric acid test (R-Biopharm, Darmstadt,
Germany).
Fractional calcium excretion was calculated using the
following formula:
100∗ (UCa∗ SCr)/(SCa∗ UCr)
where UCa is urinary calcium, SCr is serum creatinine,
SCa is serum calcium and UCr is urinary creatinine.
Estimated GFR was calculated by the following for-
mula:
[(UCr∗ Uv/SCr/Bm/24hours)
+(Uu∗ Uv/BUN/Bm/24hours)]/2
where UCr is urinary creatinine, Uv is urinary volume,
SCr is serum creatinine, Bm is body mass, and Uu is uri-
nary urea.
Western blotting
One kidney from each mouse was homogenized at
4◦C with a polytron PT10 (Kinematica AG, Switzer-
land) in radioimmunoprecipitation assay (RIPA) buffer
[1% NP-40, 0.5% sodium deoxycholate, and 0.1%
sodium dodecyl sulfate (SDS) in phosphate-buffered
saline (PBS)] containing CompleteTM protease inhibitor
(Roche Molecular Biochemicals, Mannheim, Germany).
The homogenate was lysed on ice for 1 hour and cen-
trifuged at 5000 × g for 20 minutes. The protein in
the supernatant was quantified with BCA Protein Assay
Kit (Pierce, Rockford, IL, USA) and stored at −80◦C.
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The cell lysates were mixed with Laemmli sample buffer
(Bio-Rad, Hercules, CA, USA) and incubated at
room temperature for 60 minutes. After separation on
12% SDS-polyacrylamide gel electrophoresis (PAGE),
proteins were transferred to polyvinylidine difluoride
(PVDF) membranes (Bio-Rad) in a Tris/glycine transfer
buffer (Bio-Rad) containing 10% methanol and 0.007%
SDS. Membranes were blocked with 5% nonfat milk in
Tris-buffered saline containing 0.05% Tween 20 (TBST)
for 1 hour at room temperature and then were incu-
bated overnight with a mouse monoclonal anti-TGF-
b1 primary antibody (R&D Systems, Minneapolis, MN,
USA) (1:50,000 dilution). The membranes were washed
three times for 10 minutes with TBST and incubated with
horseradish peroxidase–conjugated sheep antimouse an-
tibody (Amersham Biosciences, Piscataway, NJ, USA)
(1:3000 dilution) for 1 hour at room temperature.
After washing as above, blots were visualized by chemi-
luminescence (Western Lightning, Perkin Elmer Life Sci-
ences, Boston, MA, USA). Membranes were stripped by
washing in 100 mL of 2% SDS buffer containing 62.5
mmol/L Tris, pH 6.8, and 684 lL of 2-mercaptoethanol
at 50◦C for 20 minutes, then washed for 10 minutes with
TBST. Finally, a 60-minute block, the membranes were
reprobed with a mouse monoclonal anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) primary anti-
body (1:50,000) (US Biological, Swampscott, MA, USA).
Subsequent incubation with secondary antibody and de-
tection was as described above. Pixels on blots from eight
ClC-5 knockout and six wild-type mice were measured
using Scion Image for morphometric analysis.
Kidney histology
Kidneys were quickly excised, stripped of the renal cap-
sule, sagitally sectioned, and fixed in 4% paraformalde-
hyde in 0.1 mol/L phosphate buffer for 6 hours, and
then paraffin embedded and sectioned. Sections were de-
paraffinized with xylene and rehydrated with descending
ethanol into PBS, then stained with trichrome, hema-
toxylin and eosin, Von Kossa, or periodic acid-Schiff
(PAS). Sections were read by a renal pathologist blinded
to animal group and were graded for acute tubular injury,
largely cell swelling and vacuolization, interstitial inflam-
mation, tubular atrophy, interstitial fibrosis, increases in
glomerular mesangial matrix, and dilated tubules with or
without cystic changes using a scale of 0 to 3. The fol-
lowing criteria were used to grade pathologic lesions: 0,
pathologic lesions were present in up to 5% of the cortex;
1, pathologic lesions involving 6% to 25% of the cortical
area; 2, pathologic lesions involving 26% to 50% of the
cortical area; and 3, pathologic lesions involving more
than 50% of the cortical area. The same criteria were
used to read nephrocalcinosis in the medullary area. A
total of three to four histologic sections were analyzed for
each mouse included in Table 2. The numbers of animals
are in parenthesis.
Statistical analysis
Data are expressed as mean ± SE (N = number of
animals). Comparisons within the same mouse genotype
were assessed using analysis of variance (ANOVA) con-
sidering the different treatments as factors, and P values
less than 0.05 were considered significant. Comparisons
between ClC-5 knockout and wild-type mice were as-
sessed by using unpaired Student t test, and P values less
than 0.05 were considered significant.
RESULTS
Urinary calcium excretion
Two month old ClC-5 knockout mice and wt mice were
fed a defined high citrate diet with 0.95% calcium. Com-
pared with wild-type mice on this diet, ClC-5 knockout
mice had an average urinary calcium excretion that was
significantly and consistently elevated (Fig. 1A and B)
over a period of 4 months. When the mice were placed on
the zero citrate diet, the ClC-5 knockout mice remained
hypercalciuric compared to wild-type mice. This finding
is consistent with our previous studies that showed per-
sistent hypercalciuria of the ClC-5 knockout mice when
dietary calcium was altered from 0.95% to 0.02% [22, 23].
To study the effect of aging on dietary calcium excre-
tion, we evaluated both ClC-5 knockout and wild-type
mice for 6, 9, 12, or 17 months on either high citrate or zero
citrate diets. Again, on high citrate diet, ClC-5 knock-
out mice remained hypercalciuric compared to wt mice
(Table 1). In addition, complete removal of citrate from
the diet significantly increased urinary calcium excretion
in both ClC-5 knockout mice and wild-type mice, but the
ClC-5 knockout mice remained hypercalciuric compared
to control wild-type mice (Table 1).
Urinary sodium and potassium excretion
Compared with wild-type mice fed a high citrate diet,
ClC-5 knockout mice showed significantly elevated uri-
nary sodium excretion at 6, 9, and 12 months (Table 2).
Significant elevation of urinary sodium was observed
also in ClC-5 knockout mice fed zero citrate diet, com-
pared to 6-month-old wild-type mice fed the same diet
(Table 1). ClC-5 knockout mice and wild-type mice fed
either a high citrate or zero citrate diet showed no signif-
icant difference in urinary potassium excretion (Table 1).
There were insufficient samples to measure urinary
sodium and potassium in 9-month-old mice on zero cit-
rate diet and in 17-month-old mice on high citrate diet.
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Table 1. Summary of biochemical markers of renal function
6 months old
High citrate diet Zero citrate diet
Wild-type Knockout Wild-type Knockout
Blood urea nitrogen mg/dL 31.5 ± 1.18 (N = 6) 31 ± 2.45 (N = 9) NS 26.3 ± 0.9 (N = 12) 40.2 ± 2.5 (N = 11)a
Serum creatinie mg/dL 0.33 ± 0.01 (N = 6) 0.37 ± 0.02 (N = 9) NS 0.31 ± 0.01 (N = 12) 0.35 ± 0.03 (N = 11) NS
Glomerular filtration rate 0.19 ± 0.03 (N = 4) 0.19 ± 0.03 (N = 9) NS 0.25 ± 0.02 (11) 0.24 ± 0.02 (N = 11) NS
Urinary calcium excretion mg/24 hours 0.06 ± 0.01 (N = 6) 0.18 ± 0.02 (N = 9)a 0.18 ± 0.02 (N = 11) 0.33 ± 0.04 (N = 11)a
Urinary calcium/urinary creatinine ratio 0.12 ± 0.02 (N = 6) 0.26 ± 0.02 (N = 9)a 0.32 ± 0.03 (N = 11) 0.41 ± 0.03 (N = 11)b
Fractional calcium excretion 0.45 ± 0.06 (N = 4) 0.82 ± 0.09 (N = 9)b 1.21 ± 0.1 (N = 11) 1.7 ± 0.21 (N = 11)b
Urinary sodium/urinary creatinine ratio 1.45 ± 0.3 (N = 5) 2.52 ± 0.28 (N = 5)b 1.63 ± 0.22 (N = 6) 5.67 ± 1.18 (N = 6)a
Urinary potassium/urinary creatinine ratio 5.06 ± 0.37 (N = 5) 4.68 ± 0.67 (N = 5) NS 5.44 ± 1.07 (N = 6) 5.56 ± 0.44 (N = 6) NS
Urinary pH 6.79 ± 0.25 (N = 5) 6.06 ± 0.07 (N = 5)b 5.94 ± 0.06 (N = 6) 6.03 ± 0.07 (N = 6) NS
Urinary citrate/urinary creatinine ratio 0.43 ± 0.06 (N = 5) 0.75 ± 0.27 (N = 5) NS 0.007 ± 0.002 (N = 4) 0.014 ± 0.002 (N = 6) NS
9 months old
High citrate diet Zero citrate diet
Wild-type Knockout Wild-type Knockout
Blood urea nitrogen mg/dL 35.4 ± 1.86 (N = 5) 34.8 ± 1.92 (N = 6) NS 31 ± 2.18 (N = 6) 52.4 ± 8.33 (N = 9)b
Serum creatinine mg/dL 0.32 ± 0.02 (N = 5) 0.37 ± 0.02 (N = 6) NS 0.36 ± 0.04 (N = 6) 0.57 ± 0.09 (N = 9) NS
Glomerular filtration rate 0.23 ± 0.04 (N = 5) 0.27 ± 0.03 (N = 6) NS 0.25 ± 0.03 (N = 6) 0.13 ± 0.02 (N = 9)a
Urinary calcium excretion mg/24 hours 0.06 ± 0.01 (N = 5) 0.35 ± 0.03 (N = 6)a 0.08 ± 0.02 (N = 6) 0.18 ± 0.03 (N = 9)b
Urinary calcium/urinary creatinine ratio 0.11 ± 0.01 (N = 5) 0.34 ± 0.02 (N = 6)a 0.23 ± 0.01 (N = 6) 0.32 ± 0.03 (N = 9)b
Fractional calcium excretion 0.36 ± 0.05 (N = 5) 1.27 ± 0.12 (N = 6)a 0.85 ± 0.13 (N = 6) 1.34 ± 0.15 (N = 9)b
Urinary sodium/urinary creatinine ratio 1.49 ± 0.12 (N = 5) 4.19 ± 0.75 (N = 6)b
Urinary potassium/urinary creatinine ratio 6.7 ± 0.19 (N = 5) 5.98 ± 0.18 (N = 6)b
Urinary pH 7.97 ± 0.25 (N = 5) 6.65 ± 0.15 (N = 6)a
Urinary citrate/urinary creatinine ratio 1.62 ± 0.2 (N = 5) 1.65 ± 0.17 (N = 6) NS
12 months old
High citrate diet
Wild-type Knockout
Blood urea nitrogen mg/dL 30.4 ± 1.34 (N = 6) 50.4 ± 6.88 (N = 9)b
Serum creatinine mg/dL 0.33 ± 0.02 (N = 6) 0.38 ± 0.02 (N = 9) NS
Glomerular filtration rate 0.33 ± 0.05 (N = 6) 0.26 ± 0.03 (N = 9) NS
Urinary calcium excretion mg/24 hours 0.21 ± 0.04 (N = 6) 0.48 ± 0.06 (N = 9)a
Urinary calcium/urinary creatinine ratio 0.21 ± 0.02 (N = 6) 0.45 ± 0.16 (N = 9)a
Fractional calcium excretion 0.72 ± 0.06 (N = 6) 1.6 ± 0.2 (N = 9)a
Urinary sodium/urinary creatinine ratio 1.59 ± 0.19 (N = 6) 4.41 ± 0.71 (N = 6)a
Urinary potassium/urinary creatinine ratio 5.61 ± 0.23 (N = 6) 5.45 ± 0.46 (N = 6) NS
Urinary pH 6.55 ± 0.14 (N = 6) 5.98 ± 0.14 (N = 6)b
Urinary citrate/urinary creatinine ratio 1.29 ± 0.1 (N = 6) 1.52 ± 0.2 (N = 6) NS
17 months old
High citrate diet
Wild-type Knockout
Blood urea nitrogen mg/dL 25.3 ± 1.67 (N = 6) 98.8 ± 14.27 (N = 6)a
Serum creatinine mg/dL 0.38 ± 0.03 (N = 6) 0.85 ± 0.15 (N = 6)b
Glomerular filtration rate 0.17 ± 0.04 (N = 5) 0.07 ± 0.02 (N = 6)b
Urinary calcium excretion mg/24 hours 0.14 ± 0.02 (N = 5) 0.42 ± 0.14 (N = 6)b
Urinary calcium/urinary creatinine ratio 0.27 ± 0.01 (N = 5) 0.56 ± 0.14 (N = 6)b
Fractional calcium excretion 1.16 ± 0.1 (N = 5) 4.78 ± 1.6 (N = 6)b
ClC-5 knockout high citrate mice at the ages of 6 and 9 months have the same blood urea nitrogen, serum creatinine, and glomerular filtration rate as 6- or 9-month-old
wild-type high citrate mice, respectively (columns 1 and 2). ClC-5 knockout zero citrate mice have significantly increased blood urea nitrogen compared to wild-type
zero citrate mice at the ages of 6 and 9 months and significantly decreased glomerular filtration rate compared to wild-type zero citrate mice at the age of 9 months
(columns 3 and 4). Twelve-month-old ClC-5 knockout high citrate mice had significantly elevated blood urea nitrogen compared with 12-month-old wild-type high
citrate mice (columns 1 and 2). Seventeen-month-old ClC-5 knockout high citrate mice had significantly elevated blood urea nitrogen and serum creatinine compared
with 17-month-old wild-type high citrate mice (columns 1 and 2). Twenty-four–hour urinary calcium excretion, urinary calcium/creatinine ratio, and fractional calcium
excretion were elevated in ClC-5 knockout mice compared with matched wild-type mice at the ages of 6, 9, 12, and 17 months on high citrate diet (columns 1 and 2)
and at the ages of 6 and 9 months on zero citrate diet (columns 3 and 4). Urinary sodium/urinary creatinine ratio was significantly elevated in ClC-5 knockout mice
compared with matched wild-type mice at the ages of 6, 9 and 12 months on high citrate diet (columns 1 and 2) and at the age of 6 months on zero citrate diet (columns 3
and 4). ClC-5 knockout mice and wild-type mice fed either a high citrate or zero citrate diet showed no significant difference in urinary potassium excretion, expressed
as urinary potassium/urinary creatinine ratio (columns 1, 2, 3, and 4). Urinary pH was significantly elevated in wild-type high citrate mice compared with matched ClC-5
knockout high citrate mice at the ages of 6, 9, and 12 months (columns 1 and 2). Six-month-old ClC-5 knockout mice and wild-type mice fed zero citrate diet showed
no significant difference in urinary pH (columns 3 and 4). ClC-5 knockout mice and wild-type mice fed either a high citrate or zero citrate diet showed no significant
difference in urinary citrate excretion, expressed as urinary citrate/urinary creatinine ratio (columns 1, 2, 3, and 4).
aP < 0.01; bP < 0.05; NS P > 0.05 (unpaired t test), ClC-5 knockout vs. wild-type on the same diet.
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Fig. 1. Urinary calcium excretion of ClC-5 knockout and wild-type mice on high citrate (Hi-Cit) and zero citrate (0-Cit) diets. ClC-5 knockout mice
fed a high citrate diet had significantly elevated urinary calcium excretion compared to wild-type mice on the same diet on days 0, 60, and 120 (A
and B). ClC-5 knockout mice fed a zero citrate diet had significantly elevated urinary calcium excretion compared to wild-type mice on days 0, 30,
60, 90, and 120 (C and D). Shown are means ± SE. Urinary calcium/creatinine ratio and 24-hour calcium excretion at the beginning of experiment
when mice were fed high citrate diet is shown at days 0 to 120 (A and B). Urinary calcium/creatinine ratio and 24-hour calcium excretion of ClC-5
knockout and wild-type mice fed zero citrate diet is shown as days 0 to 120 (C and D). Time course of urinary calcium/creatinine ratio and 24-hour
calcium excretion by ClC-5 knockout and wild-type mice fed high citrate diet (days 0 to 120) (A and B). Points labeled + or ∗ were days when ClC-5
knockout mice had values significantly elevated (P < 0.01) or (P < 0.05) compared to wild-type mice.
Urinary pH
The 6-, 9-, and 12-month-old ClC-5 knockout mice
fed a high citrate diet had significantly increased uri-
nary pH compared to 6-, 9-, and 12-month-old wild-
type mice fed the same diet (Table 1). Six-month-old
ClC-5 knockout mice and wild-type mice on zero cit-
rate diet showed no significant difference in urinary
pH (Table 1). Again there were insufficient samples
to measure urinary pH in 9-month-old mice on zero
citrate diet and in 17-month-old mice on high citrate
diet.
Urinary citrate excretion
ClC-5 knockout mice and wild-type mice fed a high cit-
rate or zero citrate diet showed no significant difference in
urinary citrate excretion (Table 2). Nine-month-old mice
on zero citrate diet and in 17-month-old mice on high
citrate diet were not measured.
Serum BUN, creatinine, and GFR
To evaluate renal function in response to changes
in dietary citrate, BUN, and creatinine were measured
and GFR was calculated. Six- and 9-month-old ClC-5
knockout mice and wild-type mice fed a high citrate diet
showed no significant differences in serum creatinine,
BUN, or GFR (Table 1). Differences were observed after
12 months on a high citrate diet, when ClC-5 knockout
mice had significantly increased serum BUN and a low-
ered, but not significantly different, GFR compared with
12-month-old wild-type high citrate mice (Table 1). At
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Table 2. Summary of renal histopathologic changes seen ClC-5 knockout and wild-type mice fed a high citrate or zero citrate diet
Acute tubular Interstitial Tubular Increase in Tubular
injury inflammation atrophy Fibrosis mesangial matrix dilatations Calcinosis
Zero citrate diet (6 mo)
Wild-type (6) 0.83 ± 0.17 0 0 0 0 0
Knockout (6) 1 0.83 ± 0.11 0 0.67 ± .11 0.17 ± 0.17 0.58 ± 0.08 0
P value NS 0.00001 0.0001 0.0001 NS 0.00004 NS
ANOVA (6 mo) 5.00 (E14) 0.073, NS 0.022 0.007 NS 0.038 NS
ANOVA (9 mo) 0.0001 NS NS 0.007 NS NS NS
ANOVA (12 mo) NS NS NS NS NS NS NS
ANOVA (17 mo) NS NS NS NS NS NS NS
Zero citrate diet (9 mo)
Wild-type (6) 1.5 ± 0.34 0.75 ± 0.28 0.33 ± 0.21 0.25 ± 0.17 0 0.33 ± 0.17 0
Knockout (8) 0.88 ± 0.08 2.13 ± 0.5 1.13 ± 0.23 1.13 ± 0.26 0.44 ± 0.29 0.75 ± 0.23 0.88 ± 0.27
P value NS 0.038 0.03 0.024 NS NS 0.018
ANOVA (9 mo) 0.001 0.065, NS 0.05 0.011 NS NS 0.036
ANOVA (12 mo) NS 0.02 0.034 0.05 NS NS 0.036
ANOVA (17 mo) NS NS NS NS NS NS NS
High citrate diet (6 mo)
Wild-type (6) 0.5 ± 0.26 0.33 ± 0.11 0 0 0 0 0
Knockout (6) 0 0.5 ± 0.13 0.25 ± 0.11 0.17 ± 0.11 0 0.25 ± 0.11 0
P value NS NS 0.049 NS NS 0.049 NS
High citrate diet (9 mo)
Wild-type (6) 0.42 ± 0.2 0.33 ± 0.11 0 0 0 0 0
Knockout (6) 0.33 ± 0.11 0.92 ± 0.15 0.5 ± 0.13 0.17 ± 0.11 0 0.25 ± 0.17 0.08 ± 0.08
P value NS 0.011 0.003 NS NS NS NS
High citrate diet (12 mo)
Wild-type (6) 0.6 ± 0.24 0 0 0 0 0.5 0
Knockout (6) 0.58 ± 0.17 0.5 ± 0.16 0.42 ± 0.13 0.5 ± 0.19 0 0.67 ± 0.29 0.08 ± 0.07
P value NS 0.021 0.022 0.043 NS NS 0.036
High citrate diet (17 mo)
Wild-type (6) 1.17 ± 0.38 0.5 ± 0.13 0.17 ± 0.11 0.17 ± 0.11 0 0 0
Knockout (6) 1 ± 0.29 1.64 ± 0.43 1.21 ± 0.41 1.21 ± 0.41 0.43 ± 0.3 1.36 ± 0.39 0.5 ± 0.29
P value NS 0.038 0.04 0.04 NS 0.013 NS
Sections read by a renal pathologist blinded to animal group were graded 0 to 3 for acute tubular injury, interstitial inflammation, tubular atrophy, interstitial
fibrosis, increases in mesangial matrix, and cystic changes. The following criteria were used to grade pathologic lesions: 0, pathologic lesions were present in up to
5% of the cortex; 1, pathologic lesions involving 6% to 25% of the cortical area; 2, pathologic lesions involving 26% to 50% of the cortical area; and 3, pathologic
lesions involving more than 50% of the cortical area. The same criteria were used to read nephrocalcinosis in the medullary area. Unpaired t tests were used to
compare ClC-5 knockout vs. wild-type and to determine P value. Analysis of variance (ANOVA) was used to compare 6-month-old ClC-5 knockout mice on zero
citrate diet vs. 6-, 9-, 12-, or 17-month-old mice on high citrate diet and 9-month-old ClC-5 knockout mice on zero citrate diet vs. 9-, 12-, or 17-month old ClC-5 knock-
out mice on high citrate diet, where mouse age is designated in months (mo). NS represents P > 0.05. The number of kidney analyzed appears as values in the parentheses.
17 months of age ClC-5 knockout mice had significant
increases in serum BUN (P < 0.01) and serum creatinine
(P < 0.05), and showed significant decrease in GFR (P <
0.05) (Table 1) compared to 17-month-old wild-type mice.
Some 17-month-old ClC-5 knockout mice had elevated
GFR, whereas some mice had the same GFR as wild-type
mice. This finding is consistent with the irregular patient
to patient progression of renal failure in Dent’s disease
[27].
Renal function assessment showed clear differences
when mice were fed a zero citrate diet. Both 6- and
9-month-old ClC-5 knockout mice on a zero citrate
diet had significantly elevated serum BUN (Table 1)
(P < 0.01 and P < 0.05), compared to wild-type mice
(Table 2). GFR was significantly decreased in 9-month-
old ClC-5 knockout mice on a zero citrate diet, com-
pared to age-matched wild-type mice (Table 1). ClC-5
knockout mice showed a trend for deterioration of re-
nal function at 6 months (similar to 12-month-old ClC-5
knockout high citrate mice), manifested by significantly
increased serum BUN. A more advanced renal disease
in 9-month-old ClC-5 knockout zero citrate mice was
manifested by significantly increased serum BUN and sig-
nificantly decreased GFR (Table 1). The most dramatic
effect occurred in 9-month-old ClC-5 knockout mice that
had a renal disease defined by increases in BUN and cre-
atinine, and decreases in GFR that were comparable to
those seen in 17-month-old high citrate mice.
In summary, biologic markers of renal function show
a pattern of loss of renal function in ClC-5 knockout
mice fed a zero citrate or high citrate diet. At the age of
6 months on a zero citrate diet or 12 months on a high
citrate diet ClC-5 knockout mice had very early signs
of renal disease. At 9 months on a zero citrate diet or
17 months on a high citrate diet ClC-5 knockout mice
had renal insufficiency. These data suggest that a high
citrate diet preserved renal function and delayed the on-
set of renal insufficiency in ClC-5 knockout mice. The
renal function of wild-type mice was not affected by
citrate.
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Fig. 2. Representative histological stains of kidneys from ClC-5 knock-
out mice on high citrate or zero citrate diets. (A) The cortex of a
9-month-old ClC-5 knockout high citrate mouse stained with trichrome
blue, shows well-preserved tubular structures and absence of fibrosis
(lack of blue collagen staining), whereas (B) that of a 9-month-old ClC-5
knockout zero citrate mouse shows lymphocytic or lymphoplasmacytic
infiltrate (arrows). (C and D) Trichrome blue staining of the cortex of
a 9-month-old ClC-5 knockout zero citrate mouse. (E) The cortex of a
17-month-old ClC-5 knockout high citrate mouse stained with
Trichrome blue. (C to E) Interstitial fibrosis is marked by arrows. (F and
G) Von Kossa staining indicates that the inner medulla of a 9-month-
old ClC-5 knockout zero citrate mouse and (H) that of a 17-month-old
ClC-5 knockout high citrate mouse show intratubular calcium deposits
(arrowheads). Bars represent 50 lm (A and G) [magnification 10× (A
to E) and 20× (F to H)].
Histologic data
We also performed a histologic analysis of the tissue in
order to evaluate renal function. Nine-month-old ClC-5
knockout high citrate mice had an overall normal kid-
ney architecture (Fig. 2A). ClC-5 knockout zero citrate
or high citrate mice showed levels of acute tubular in-
jury comparable to age- and diet-matched wild-type mice
(Table 1). Six-month-old ClC-5 knockout zero citrate
mice had a significant increase in acute tubular injury
compared to 6- or 9-month-old ClC-5 knockout high
citrate mice (Table 2). Nine-month-old ClC-5 knockout
zero citrate mice had a significant increase in acute tubu-
lar injury compared to 9-month-old ClC-5 knockout high
citrate mice (Table 2). These data imply that zero citrate
significantly increased acute tubular injury.
On a high citrate diet, 9-, 12-, and 17-month-old ClC-5
knockout mice had significantly increased interstitial in-
flammation compared with their wild-type counterparts
(Table 2). Six- and 9-month-old ClC-5 knockout mice fed
a zero citrate diet showed significantly increased intersti-
tial inflammation compared to wild-type zero citrate mice
(Table 2). A representative kidney section of a 9-month-
old ClC-5 knockout zero citrate mouse (Fig. 2B) shows
lymphocytic and lymphoplasmacytic infiltration.
Tubular atrophy was significantly increased in 6- and
9-month-old ClC-5 knockout zero citrate mice com-
pared to 6- and 9-month-old wild-type zero citrate mice
(Table 2). Six-month-old ClC-5 knockout zero citrate
mice had a significant increase in tubular atrophy com-
pared to age-matched ClC-5 knockout high citrate mice
(Table 2). Nine-month-old ClC-5 knockout zero citrate
mice had a significant increase in tubular atrophy com-
pared to 9- or 12-month-old ClC-5 knockout high citrate
mice (Table 2). This level of atrophy was comparable to
that found in 17-month-old ClC-5 knockout high citrate
mice (Table 2). Cortical sections from 9-month-old ClC-5
knockout high citrate mice showed well-preserved tubu-
lar structures (Fig. 2A), whereas those from 9-month-
old ClC-5 knockout zero citrate mice and 17-month-old
ClC-5 knockout high citrate mice have tubular atrophy
(Fig. 2C, D, and E, arrowheads, respectively).
Six- and 9-month-old ClC-5 knockout zero citrate mice
had significantly increased interstitial fibrosis, compared
to age-matched wild-type zero citrate mice (Table 2). Six-
month-old ClC-5 knockout zero citrate mice had a sig-
nificant increase in interstitial fibrosis compared with 6-
and 9-month-old ClC-5 knockout high citrate mice (Ta-
ble 2). Nine-month-old ClC-5 knockout zero citrate mice
had a significant increase in interstitial fibrosis compared
with 9- and 12-month-old ClC-5 knockout high citrate
mice (Table 2). The fibrosis in these mice was compa-
rable to that seen in the 17-month-old ClC-5 knockout
high citrate mice. Representative kidney sections of 9-
month-old ClC-5 knockout zero citrate mice (Fig. 2C and
D) and 17-month-old ClC-5 knockout high citrate mice
(Fig. 2E) show fibrosis (blue collagen staining), whereas
a 9-month-old ClC-5 knockout high citrate mice did not
show fibrosis (lack of blue collagen staining) (Fig. 2A).
In conclusion, zero citrate diet significantly increased in-
terstitial fibrosis in 6- and 9-month-old ClC-5 knockout
mice.
Six- and 9-month-old ClC-5 knockout zero citrate mice
and 17-month-old ClC-5 knockout high citrate mice did
not have a significant increase in mesangial matrix com-
pared with matched wild-type mice (Table 2). Mesangial
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matrix in 6- or 9-month-old ClC-5 knockout zero citrate
mice was comparable to 6-, 9-, 12-, or 17-month-old ClC-5
knockout high citrate mice (Table 2). These data suggest
that mesangial matrix in ClC-5 knockout mice was not
affected by dietary citrate.
Six-month-old ClC-5 knockout zero citrate mice had a
significant increase in tubular dilation and cystic changes
compared to 6-month-old wild-type zero citrate mice or
6-month-old ClC-5 knockout high citrate mice, whereas
9-month-old ClC-5 knockout zero citrate mice did not
show a significant increase in tubular atrophy and cystic
changes compared to 9-month-old wild-type zero citrate
mice or 9-month-old ClC-5 knockout high citrate mice
(Table 2). Seventeen-month-old ClC-5 knockout high cit-
rate mice had a significant increase in tubular atrophy and
cystic changes compared to 17-month-old wild-type high
citrate mice (Table 2). These data suggest that dietary cit-
rate had no effect on tubular dilation and cystic changes.
Renal medullary calcinosis was significantly increased
in 9-month-old ClC-5 knockout zero citrate mice
compared to 9-month-old wild-type zero citrate mice
(Table 2). Four kidneys from 9-month-old ClC-5 knock-
out zero citrate mice stained using the Von Kossa method
were examined, three mice had mild nephrocalcinosis
and one mouse had moderate to severe nephrocalcinosis.
Two representative sections are shown in Figure 2G and
H. These calcifications are similar to those described by
Moulin et al [28] in Dent patients. Nine- and 12-month-
old ClC-5 knockout high citrate mice showed significantly
diminished calcinosis compared to 9-month-old ClC-5
knockout zero citrate mice. Six kidneys from 9-month-
old ClC-5 knockout high citrate mice were examined and
only one had mild nephrocalcinosis. In the 12-month-
old group, one out of six ClC-5 knockout high citrate
mice had mild to moderate nephrocalcinosis. There was
a moderate to severe nephrocalcinosis in one mouse and
mild nephrocalcinosis in two out of six of the 17-month-
old high citrate mice. A representative section is shown
in Figure 2H. Note that the amount of calcinosis in 17-
month-old ClC-5 knockout mice on a high citrate diet was
comparable to 9-month-old ClC-5 knockout zero citrate
mice. In conclusion, the zero citrate diet was associated
with significantly increased nephrocalcinosis.
TGF-b1
Nine-month-old ClC-5 knockout zero citrate mice
(N = 5) had much greater TGF-b1 in total kidney lysates
compared with 9-month-old wild-type zero citrate mice
(N = 4) (Fig. 3, Western blot). In a comparison of six
wild-type kidneys and eight ClC-5 knockout kidneys the
TGF-b1 was significantly increased in ClC-5 knockout
mice (Fig. 3C). On overexposure of the blots, 6-, 9-, and
12-month-old ClC-5 knockout high citrate mice and 6-
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Fig. 3. ClC-5 knockout (KO) mice have elevated transforming growth
factor-b1 (TGF-b1). Western blot analysis of TGF-b1 (A) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (B) from kid-
neys of 9-month-old ClC-5 knockout and wild-type (WT) zero citrate
mice. (A) TGF-b1 was greatly elevated in five out of five ClC-5 knock-
out mice and somewhat elevated in one out of four wild-type mice.
GAPDH was used as an internal control and its expression was nearly
identical in ClC-5 knockout and wild-type mice (B). (C) Comparison of
the quantifications of the TGF-b1 signals expressed as average pixels
and standard errors, from eight ClC-5 knockout and six wild-type mice,
∗P < 0.05 (unpaired t test).
month-old ClC-5 knockout zero citrate mice revealed
barely detectable levels of TGF-b1 (data not shown).
DISCUSSION
In the present study, we found that ClC-5 knock-
out zero citrate mice develop renal insufficiency by the
age of 9 months, whereas the development of a similar
stage of renal insufficiency in ClC-5 knockout high cit-
rate mice was delayed to about 12 to 17 months. High
citrate diet preserves renal function, as measured by
many parameters, including histologic changes, cytokines,
and urine chemistry. The high citrate diet appears to
slow the progression to advanced stages of renal disease
in ClC-5 knockout mice, even in the absence of stone
formation.
Clinical features of Dent’s disease, caused
by mutations in CLC-5, include hypercalciuria,
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low-molecular-weight proteinuria, nephrocalcinosis,
nephrolithiasis, and renal failure. Almost all of the males
affected with Dent’s disease present with hypercalciuria
[2, 27]. The ClC-5 knockout mouse produced at Johns
Hopkins University has hypercalciuria at ages 6 weeks to
17 months, on both normal calcium [22] and low calcium
diets [23], whether 24-hour calcium excretion, calcium
creatinine ratio, or fractional excretion of calcium are
evaluated. We now show that ClC-5 knockout mice re-
main hypercalciuric compared to wild-type mice on zero
citrate diet and that this hypercalciuria persists over many
months. This finding is quite different from the outcome
found in the Jentsch mouse model that does not have
hypercalciuria [26]. Moreover, that mouse model did
not have calcifications, which could be explained by
lack of hypercalciuria [5]. The reasons for the lack
of hypercalciuria in the Jentsch mouse model are not
known. However, because the Hopkins ClC-5 knockout
mouse model has elevated 1a,25 dihydroxyvitamin D3,
it is possible that a small amount of intestinal calcium
absorption enables the hyperexcretion of calcium.
Almost half of the Dent’s disease patients have stones
[27, 29] and about two thirds of patients have variable
degrees of medullary nephrocalcinosis [2, 24, 27, 30]. Hy-
percalciuria and hypocitraturia are two major metabolic
risk factors contributing to the generalized condition of
nephrolithiasis. Citrate has an inhibitory effect against
the crystallization of stone-forming calcium salts [18] by
binding to calcium and lowering ionic calcium in the
urine [19]. Dent’s disease patients have been reported
to have normal urinary citrate, except those with re-
duced renal function who have hypocitraturia [2]. In the
present study, nephrocalcinosis (calcium deposits identi-
fied by Von Kossa staining) was significantly increased in
9-month-old ClC-5 knockout zero citrate mice compared
with age-matched wild-type mice, and the calcinosis of
the 9-month-old ClC-5 knockout mice was comparable to
that of 17-month-old ClC-5 knockout high citrate mice.
We did not see evidence of stones in the ClC-5 knockout
mice for several possible reasons. First, the stones could
be too small to be detected by the conventional mag-
netic resonance imaging (MRI) scans to which we had
access (data not shown). Second, the mice could form
fewer stones than humans, and/or they may need to be
monitored over a longer time period.
Recurrent renal stones and nephrocalcinosis can be
managed with increased volume intake, dietary mod-
ification, and thiazide and potassium citrate in the
case of hypocitraturia. Thiazide might reduce recurrent
nephrolithiasis in Dent’s disease patients by decreas-
ing urinary calcium excretion [31], but it is not known
whether thiazide would have any long-term benefit in
protecting renal function in these patients. A recent study
did show a reduction in calcium excretion with thiazide
in Dent’s disease patients, but this study was performed
over a short time period so changes in renal pathology
were not addressed.
Renal fibrogenesis leads to end-stage renal failure
in a number of renal diseases, including obstructive
nephropathy [32]. In the initial phase, mononuclear cells
infiltrate the interstitium. This leads to the activation
and proliferation of fibroblasts that in turn are thought
to increase the interstitial matrix [33]. Proximal tubular
cells become hypertrophied in order to compensate for
the functional loss. This is followed by tubular atrophy
[33]. Excessive deposition of matrix results in destruc-
tion of kidney structure and decreased renal function
[34]. Dent’s disease patients have inflammatory changes,
tubular atrophy, interstitial fibrosis, and glomeruloscle-
rosis [2, 24, 35]. Wrong, Norden, and Feest [2] also de-
scribed numerous small cysts in one third of the Dent’s
disease patients. Interstitial inflammation, tubular atro-
phy, and interstitial fibrosis were significantly increased
in 6- and 9-month-old ClC-5 knockout zero citrate mice
compared to age- and diet-matched wild-type mice. There
was a significantly increased interstitial inflammation in
9-month-old ClC-5 knockout zero citrate mice compared
to 6-month-old ClC-5 knockout zero citrate mice (data
not shown). Interstitial fibrosis was noted to be minor
to moderate in 6-month-old ClC-5 knockout zero citrate
mice and comparable to 12-month-old ClC-5 knockout
high citrate mice. In 9-month-old ClC-5 knockout zero
citrate mice interstitial fibrosis and tubular atrophy were
mild to moderate and comparable to 17-month-old ClC-5
knockout high citrate mice. Although some ClC-5 knock-
out high citrate mice had minor to mild tubular atrophy
and/or interstitial fibrosis at 9 or 12 months, these histo-
logic changes were significantly decreased compared to
9-month-old ClC-5 knockout zero citrate mice. These
findings demonstrate that the interstitial fibrosis and
tubular atrophy can be delayed in ClC-5 knockout mice
fed a high citrate diet on a long-term basis.
Increased levels of TGF-b1, a fibrogenic cytokine, both
stimulates the synthesis of extracellular matrix protein
[36] and chemoatractants, as well as activates fibroblasts
[37, 38], leading to tubular atrophy, tubulointerstitial fi-
brosis, and glomerulosclerosis [39]. Tubular obstruction
leads to increases in TGF-b1 [36]. Proximal tubular cells
may contribute to the progression of renal disease by syn-
thesizing TGF-b1 [40–42]. TGF-b1 was increased in kid-
neys of 9-month-old ClC-5 knockout zero citrate mice
compared to kidneys of 9-month-old wild-type zero cit-
rate mice. In 9- and 12-month-old ClC-5 knockout and
wild-type high citrate mice, TGF-b1 was undetectable.
Although TGF-b1 is elevated in a number of progressive
renal diseases [43], it appears that in ClC-5 knockout mice
the activation of TGF-b1 cascade is most closely related
to calcinosis and interstitial fibrosis.
Wrong, Norden, and Feest [2] found that 9 out of 11 of
his Dent’s disease patients had varying degrees of renal
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failure at the age of 47 ± 13 years, whereas Frymoyer et
al [24] found some degree of renal failure in seven out of
eight patients between the age of 9 and 54 years. The av-
erage mouse life span is 24 ± 6 months. The ClC-5 knock-
out zero citrate mice had renal insufficiency at 9 months,
whereas the ClC-5 knockout high citrate mice had renal
insufficiency at 17 months, each group showing increased
serum creatinine and BUN, and decreased GFR. Some
ClC-5 knockout mice of the zero citrate cohort showed
the first signs of renal disease with increased BUN at
6 months of age, but it was only at 12 months of age
that some ClC-5 knockout high citrate mice showed in-
creased BUN. Furthermore, ClC-5 knockout zero citrate
mice develop signs of renal insufficiency with increased
serum creatinine, increased BUN, and decreased GFR at
9 months age, whereas ClC-5 knockout high citrate mice
did not develop similar signs until 17 months. Dietary cit-
rate appears to delay the progression of renal disease,
significantly preserving renal function in ClC-5 knockout
mice compared to animals on a zero citrate diet.
The present study documents the progression of re-
nal disease in the Johns Hopkins ClC-5 knockout mouse
model. Dietary citrate apparently prolongs renal function
in these mice despite the absence of stones and rather spo-
radic evidence of nephrocalcinosis. Maintenance of this
mouse on zero citrate diet enables further studies of de-
velopment of renal disease and the identification of new
markers of impending renal function loss. If the results
of the present study on a mouse model can be applied
to human renal function in Dent’s disease patients, the
use of long-term dietary citrate supplementation would
possibly delay progression of the renal disease.
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